Full Press Release Details
Priveterra Acquisition Corp. Announces Intention
to Transfer to NYSE Upon Completion of Business Combination with AEON Biopharma, Inc.
FORT LAUDERDALE, FL- July 11, 2023- Priveterra Acquisition Corp.
(Nasdaq: PMGM) ("Priveterra" and, after the consummation of its pending business combination (the "Business Combination")
and following its name change to AEON Biopharma, Inc., "New AEON") today announced that, upon the Business Combination
with AEON Biopharma, Inc, ("AEON") following which AEON will be a wholly owned subsidiary of Priveterra and Priveterra
will change its name to AEON Biopharma, Inc., New AEON Common Stock will be listed on NYSE American LLC ("NYSE"). The
decision to list on NYSE was made in connection with the Business Combination and enables the combined company to be listed alongside
other innovative companies that are also listed on NYSE.
Trading is expected to begin on NYSE on or about July 24, 2023,
under the new ticker symbol "AEON" for the New AEON Common Stock following the consummation of the Business Combination, which
is currently expected to occur on or about July 24, 2023, subject to satisfaction or waiver of other customary closing conditions.
Until the Business Combination and transfer to NYSE is complete, the PMGM Ordinary Shares, warrants, and units will continue to trade
under the ticker symbols "PMGM," "PMGMW," and "PMGMU," respectively, on the Nasdaq Stock Market LLC
("Nasdaq"). The last day of trading on Nasdaq is expected to be on or about July 21, 2023.
No action is required by existing PMGM shareholders with respect to
the ticker symbol or exchange listing change.
About Priveterra Acquisition Corp.
Priveterra Acquisition Corp. (NASDAQ: PMGM) is a blank-check company
formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination
with one or more businesses in life sciences. Priveterra is sponsored by Robert Palmisano and Priveterra Capital, LLC.
Forward-Looking Statements
This Current Report on Form 8-K includes "forward-looking
statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.
Forward-looking statements generally relate to future events involving, or future performance of, the Company or AEON. In some cases,
you can identify forward-looking statements by terminology such as "pro forma", "may", "should", "could",
"might", "plan", "possible", "project", "strive", "budget", "forecast",
"expect", "intend", "will", "estimate", "anticipate", "believe",
"predict", "potential" or "continue", or the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to
differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon
estimates and assumptions that, while considered reasonable by the Company and its management, and AEON and its management, as the case
may be, are inherently uncertain. Certain risks and uncertainties are set forth in the section entitled "Risk Factors" and
"Cautionary Note Regarding Forward-Looking Statements" in the Company's final prospectus dated February 11, 2021,
relating to its IPO and other risks and uncertainties indicated from time to time in the definitive proxy statement to be delivered to
the Company's stockholders and related S-4 Registration Statement, including those set forth under "Risk Factors" therein,
and other documents filed to be filed with the SEC by the Company.
Priveterra Acquisition Corp.